Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I first-in-human, single ascending clinical study assessing OSM 0205

Next Previous
X
Search
Trial Profile

A phase I first-in-human, single ascending clinical study assessing OSM 0205

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OSM-0205 (Primary)
  • Indications Peripheral neuropathies
  • Focus Adverse reactions; First in man
  • Sponsors Osmol Therapeutics

    • Most Recent Events

    • 18 Sep 2023 According to Osmol Therapeutics media release, that the U.S. Food and Drug Administration (FDA) notified the company that the first-in-human clinical trial of OSM-0205 in healthy subjects for the prevention of CIPN may proceed.
    • 01 Aug 2023 According to Osmol Therapeutics media release, the compay has filed the Investigational New Drug application (IND) with the FDA for OSM-0205.
    • 12 Apr 2022 According to Osmol Therapeutics media release, the company expect to file IND later this year and initiate this trial in the first half of 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top